drugset / Trial / NCT02513550
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis
RandomizedParallel-groupDouble-blindTreatment
Summary
The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis.
Timeline
- Start
- 2015-08
- Primary completion
- 2016-11
- Completion
- 2017-08-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixekizumab | Monoclonal antibody | 80 mg | Subcutaneous |